Insmed Incorporated - Common Stock (INSM)
90.93
+20.25 (28.65%)
NASDAQ · Last Trade: Jun 10th, 5:37 PM EDT
Detailed Quote
Previous Close | 70.68 |
---|---|
Open | 88.64 |
Bid | 90.15 |
Ask | 90.85 |
Day's Range | 86.00 - 91.86 |
52 Week Range | 56.03 - 84.91 |
Volume | 15,929,235 |
Market Cap | 10.48B |
PE Ratio (TTM) | -15.33 |
EPS (TTM) | -5.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,280,875 |
Chart
About Insmed Incorporated - Common Stock (INSM)
Insmed Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with serious and rare diseases. The company specializes in creating treatments for conditions related to severe respiratory infections, particularly those caused by non-tuberculous mycobacteria. Insmed’s research and development efforts are driven by a commitment to address unmet medical needs, utilizing advanced science and technology to bring forward new options for patients who often have limited alternatives. Through their clinical programs, Insmed aims to improve health outcomes and enhance the quality of life for individuals suffering from these challenging conditions. Read More
News & Press Releases
Via Benzinga · June 10, 2025
Via Benzinga · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025

Via Benzinga · March 5, 2025
Via Benzinga · June 10, 2025
Insmed said that it will immediately engage with the U.S. Food and Drug Administration (FDA) regarding a late-stage study design following the positive results from the mid-stage trial.
Via Stocktwits · June 10, 2025
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via Investor's Business Daily · June 10, 2025
Via Benzinga · May 13, 2025
Via Benzinga · May 9, 2025
Via Benzinga · April 25, 2025
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Via Benzinga · April 20, 2025
Via Benzinga · April 15, 2025
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · April 11, 2025
INSMED INC (NASDAQ:INSM) Reveals Intriguing Technical Aspects. Indications Suggest NASDAQ:INSM Could Be on the Verge of a Breakout. Here's What You Need to Know.
Via Chartmill · March 28, 2025
Via Benzinga · March 25, 2025
Via The Motley Fool · March 15, 2025

Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines.
Via Benzinga · March 6, 2025

First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%.
Via Benzinga · February 28, 2025